In This Article:
Supported by operational growth of 6.7%, Johnson & Johnson (JNJ, Financials) reported a 5.3% rise in fourth-quarter revenues to $22.5 billion. With operational growth of 5.9% except for COVID-19 vaccination contributions, full-year 2024 revenues increased 4.3% to $88.8 billion.
With adjusted EPS at $2.04 and fourth-quarter EPS at $1.41, $0.22 in costs related to the V-Wave purchase accounted for. EPS for the year was $5.79; adjusted EPS, incorporating $0.67 in charges for many acquisitions, was $9.98.
With operating sales of 7.5% excluding the COVID-19 vaccine, the Innovative Medicine section drove increase. Important players were medications like Spravato (esketamine), Darzalex (daratumumab), and Tremfya (guselkumab). Thanks in part to advances in cardiology and electrophysiological technologies, MedTech revenues grew 6.2%.
While full-year net profits rose 5.6% to $14.1 billion, quarter net earnings dropped 17% to $3.4 billion. < Factors influencing profitability mentioned by the corporation were increased R&D costs and acquisition-related expenditures.
Reflecting mid-point growth of 8.7%, Johnson & Johnson released 2025 projection with operational sales predicted to expand between 2.5% and 3.5%, and adjusted operational EPS estimated to range from $10.75 to $10.95.
Positive trial findings for Rybrevant and Lazcluze in lung cancer, regulatory progression for TAR-200 in bladder cancer, and CE Mark clearance for the OTTAVA robotic surgical system marked pipeline developments throughout the year. The corporation also underlined its leadership in neuroscience, immunology, and cancer.
Emphasizing investments on innovation and the company's capacity to solve illnesses with great unmet demand, CEO Joaquin Duato said 2024 is transforming. The business underlined once again its dedication to propel expansion with a strong financial basis and unique product range.
This article first appeared on GuruFocus.